A continued display of strong demand for products and services resulting in organic growth above target, complemented by EBITDA levels paving the way for reaching profitability in 2022
BICO is the future of life-saving treatments. We are reducing the organ shortage and speeding up drug development by providing accessible life science solutions that combine biology and technology.
January -
- Net sales amounted to MSEK 477.2 (129.5), which corresponded to an increase of 268% (241) compared to the corresponding period previous year. Organic growth amounted to 52% (62).
- Adjusted EBITDA amounted to MSEK 6.0 (-12.7), which corresponded to a margin of 1.3% (-9.8).
- EBITDA amounted to MSEK -19.4 (-34.9), corresponding to a margin of -4.1% (-26.9).
-
Net profit/loss for the period amounted to MSEK -43.5 (-47.8), corresponding to earnings per share before and after dilution of
SEK -0.68 (-0.90).
- The gross margin amounted to 73.9% (77.3). The gross margin is slightly higher than the average for 2021. In Q1 2021, the gross margin was higher primarily due to a high share of service revenues.
- Cash flow from operating activities amounted to MSEK -69.2 (-29.3, of which MSEK -58.6 (-38.6) was attributable to inventory build-up during the quarter).
"Following an acquisition-intense period in 2021, BICO's focus has moved to integration, building commercial success through technical and administrative synergies between our acquisitions, as well as across our three business areas Bioprinting, Biosciences and Bioautomation. Our goal is positive EBITDA for the full year 2022, which we are on track to achieve."
Erik Gatenholm, CEO and President, BICO
Invitation to presentation:
Join us for combined presentation audiocasts and telephone conferences with the opportunity to ask questions at
The presentation audiocasts will be accessible via the following links:
Morning audiocast, at
https://tv.streamfabriken.com/bico-q1-2022-am
To participate via telephone, please call any of the following numbers:
SE: +46 856 642 703
US: +1 631 91 314 226
PIN for US: 46659360#
Afternoon audiocast, at
https://tv.streamfabriken.com/bico-q1-2022-pm
To participate via telephone, please call any of the following numbers:
SE: + 46 850 558 352
US: +1 6319 131 422
PIN for US: 36222967#
The presentation will also be available on the company's website: https://bico.com/investors/earnings-calls/
For further information, please contact:
Erik Gatenholm, President & CEO,
Phone: +46 73 267 0000
E-mail: eg@bico.com
Åsa Hillsten, SVP &Head of Investor Relations,
Phone: +46 70 0 81 81 17
E-mail: ash@bico.com
This information is information that
About BICO
Founded in 2016, BICO (formerly
https://news.cision.com/bico-group/r/bico-publishes-interim-report-january---march-2022--continued-growth-in-sales--improved-profitabilit,c3569188
https://mb.cision.com/Main/14960/3569188/1581079.pdf
https://mb.cision.com/Public/14960/3569188/a150a5797fc15299.pdf
(c) 2022 Cision. All rights reserved., source